Interactions between ibrutinib and anti-CD20 antibodies: Competing effects on the outcome of combination therapy

Clinical Cancer Research

Volumn 22, Issue 1, 2016, Pages 86-95

  Skarzynski, Martin ^a   Niemann, Carsten U ^a   Lee, Yuh Shan ^a   Martyr, Sabrina ^a   Maric, Irina ^a   Salem, Dalia ^a   Stetler Stevenson, Maryalice ^a   Marti, Gerald E ^a   Calvo, Katherine R ^a   Yuan, Constance ^a   Valdez, Janet ^a   Soto, Susan ^a   Farooqui, Mohammed Z H ^a   Herman, Sarah E M ^a   Wiestner, Adrian ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENT COMPONENT C3D; DECAY ACCELERATING FACTOR; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OFATUMUMAB; ANTINEOPLASTIC AGENT; COMPLEMENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RITUXIMAB;

ANTIGEN EXPRESSION; ARTICLE; BINDING SITE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CD20 GENE; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RESPONSE; EX VIVO STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; OPSONIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR CELL; BIOPSY; BONE MARROW; CYTOTOXICITY; DRUG EFFECTS; DRUG INTERACTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PATHOLOGY;

ANTIGENS, CD20; ANTIGENS, CD55; ANTINEOPLASTIC AGENTS; BIOPSY; BONE MARROW; CLINICAL TRIALS, PHASE II AS TOPIC; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DRUG INTERACTIONS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NF-KAPPA B; PYRAZOLES; PYRIMIDINES; RITUXIMAB; RNA, MESSENGER;

EID: 84954551249     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1304     Document Type: Article

References (50)

1. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31:88-94.
2. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
3. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.
4. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in Previously Treated Waldenström's Macroglobulinemia. N Engl J Med 2015;372:1430-40.
5. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21:922-6.
6. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with highrisk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014;15:1090-9.
7. Wang M, Gordon LI, Rule S, Goy A, Hermine O, Rizo A, et al. A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL). J Clin Oncol 31:15s, 2013 (suppl; abstr TPS8613).
8. Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood 2015;126:842-50.
9. Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 2015; 125:2915-22.
10. Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood 2015;125:242-8.
11. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74.
12. Herman SE, Niemann CU, Farooqui M, Jones J, Mustafa RZ, Lipsky A, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28:2188-96.
13. Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013;27:173-206.
14. Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, et al. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia 2014; 28:1163-7.
15. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383-9.
16. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complementinduced cell death by rituximab depends onCD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006;12:4027-35.
17. Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Esteve J, Campo E, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001;98:2771-7.
18. Taylor RP, Lindorfer MA. The role of complement in mAb-based therapies of cancer. Methods 2014;65:18-27.
19. Wang S-Y, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Exp Opin Biol Ther 2008;8:759-68.
20. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47: 115-23.
21. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014;123:1957-60.
22. Borge M, Almejún MB, Podaza E, Colado A, Grecco HF, Cabrejo M, et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica 2015;100:e140-e2.
23. Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 2015;100:77-86.
24. Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2015;16:169-76.
25. Jasper GA, Arun I, Venzon D, Kreitman RJ, Wayne AS, Yuan CM, et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom 2011;80:83-90.
26. Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 2014;123:3286-95.
27. Lindorfer MA, Jinivizian HB, Foley PL, Kennedy AD, Solga MD, Taylor RP. B Cell Complement Receptor 2 Transfer Reaction. J Immunol 2003;170: 3671-8.
28. Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptorexpressing effector cells than direct internalization by the B cells. JImmunol 2011;187:3438-47.
29. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176:2600-9.
30. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 2008;181:8120-32.
31. Chen FE, Huang D-B, Chen Y-Q, Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-[kappa]B bound to DNA. Nature 1998;391:410-3.
32. Linnell J, Mott R, Field S, Kwiatkowski DP, Ragoussis J, Udalova IA. Quantitative high-throughput analysis of transcription factor binding specificities. Nucleic Acids Res 2004;32:e44.
33. Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP, et al. Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol 2011;18:463-70.
34. Taylor RP, Lindorfer MA. Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood 2015;125:762-6.
35. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012;188: 3532-41.
36. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280-8.
37. Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pettinger AM, et al. Induced resistance to ofatumumab mediated cell clearance mechanisms, including complement dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol 2014;192:1620-9.
38. Lindorfer MA, Wiestner A, Zent CS, Taylor RP. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? Oncoimmunology 2012;1:959-61.
39. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012;120:1175-84.
40. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013;34:592-601.
41. Gros P, Milder FJ, Janssen BJC. Complement driven by conformational changes. Nat Rev Immunol 2008;8:48-58.
42. Carter D, Lieber A. Protein engineering to target complement evasion in cancer. FEBS Lett 2014;588:334-40.
43. Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T. Complement in antibody-based tumor therapy. Crit Rev Immunol 2014;34:199-214.
44. Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW. Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics. Mol Immunol 2015;67:117-30.
45. Gul N, Babes L, Siegmund K, Korthouwer R, Bogels M, Braster R, et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. The J Clin Invest 2014;124:812-23.
46. Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, VanRooijen N, et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 2013;123:5098-103.
47. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177:7435-43.
48. Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010;95:329-32.
49. Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, et al. Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab is Effective and Tolerable and Limits Loss of CD20 Expression by Circulating CLL Cells. Am J Hematol 2014;89:757-65.
50. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119:1182-9.